Pharmaceutical composition containing calcium antagonist, ACE inhibitor and statins

A technology of calcium ion antagonists and compositions, applied in the field of medicine, capable of solving unsatisfactory problems

Inactive Publication Date: 2010-03-03
王丽燕
View PDF7 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the compound preparation has an obvious antihypertensive effect and reduces cardiovascular morbidity and / or mortality, it is still unsatisfactory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing calcium antagonist, ACE inhibitor and statins
  • Pharmaceutical composition containing calcium antagonist, ACE inhibitor and statins
  • Pharmaceutical composition containing calcium antagonist, ACE inhibitor and statins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0155] Embodiment 1: Levoamlodipine besylate, perindopril tert-butylamine salt and atorvastatin calcium tablet

[0156]

[0157] Preparation:

[0158] (1) Granulation of atorvastatin calcium granules

[0159] Step 1. Pass various solid raw and auxiliary materials through No. 5 to No. 6 sieves, and set aside;

[0160] Step 2, dissolving polysorbate 80 in purified water at 45°C to 60°C, adding hydroxypropyl cellulose, and cooling the solution to room temperature;

[0161] Step 3, mixing atorvastatin calcium, calcium carbonate, microcrystalline cellulose, precrosslinked starch, crospovidone and croscarmellose sodium in a granulator;

[0162] Step 4. Mix the powder mixture from step 3 and the solution from step 2 in the granulator, and stir while adding to make a suitable soft material. If necessary, adjust its pH to 5.5-10.0. Use No. 2 Sieve to make wet granules;

[0163] Step 5, dry the granules in the drying equipment, sieve the granules with No. 2 sieve after drying, an...

Embodiment 2

[0169] Embodiment 2: amlodipine besylate, fosinopril sodium and simvastatin capsules

[0170]

[0171]

[0172] Preparation:

[0173] (1) Granulation of Simvastatin Granules

[0174] Step 1. Pass various solid raw and auxiliary materials through No. 5 to No. 6 sieves, and set aside;

[0175] Step 2, dissolving polysorbate 80 in purified water at 50°C and adding hydroxypropyl cellulose, and cooling the solution to room temperature;

[0176] Step 3, mixing simvastatin, calcium carbonate, microcrystalline cellulose, precrossified starch, sodium lauryl sulfate and croscarmellose sodium in a granulator;

[0177] Step 4. Mix the powder mixture from step 3 and the solution from step 2 in the granulator, and stir while adding to make a suitable soft material, and adjust its pH value to 5.5-10.0 if necessary; use No. 2 Sieve to make wet granules;

[0178] Step 5, dry the granules in the drying equipment, sieve the granules with No. 2 sieve after drying, and finally make the m...

Embodiment 3

[0184] Embodiment 3: levamlodipine besylate, ramipril and atorvastatin calcium dispersible tablet

[0185]

[0186]

[0187] Preparation:

[0188] (1) Preparation of Atorvastatin Calcium Microcapsules

[0189] Step A, pass various solid raw and auxiliary materials through No. 5 to No. 6 sieves respectively, and set aside;

[0190] Step B. Dissolve gelatin and gum arabic in purified water respectively, stir to make them fully dissolved, add atorvastatin calcium and cross-linked carboxymethyl cellulose sodium to gum arabic, ultrasonic emulsify for 45 minutes, and gelatin solution and Mix the gum arabic solution into a three-necked flask, control the stirring speed at 200-400rpm, heat in a water bath, keep the temperature at 45°C-50°C, adjust the pH value of the system to 3.5-4.0, conduct the condensation reaction for 55 minutes, and lower the temperature of the system to 2 ℃-8℃, add formaldehyde with a mass concentration of 25% and a glutaraldehyde solution with a mass c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition which comprises: calcium cannel blocker (CCB) or pharmaceutically acceptable salt of the CCB, angiotensin-converting enzyme inhibitor (ACEI) and pharmaceutically acceptable salt of the ACEI, statins or pharmaceutically acceptable salt of the statins, and pharmaceutically acceptable carrier. The invention also relates to a kit containing the active substance. The pharmaceutical composition and the kit are used for treating hypertension, dyslipidemia, cerebral apoplexy, coronary disease, diabetes mellitus, complications of diabetes, angina, myocardial infarction, cardiac insufficiency, renal dysfunction, atherosclerosis, ventricular hypertrophy, aneurysm, myocardial ischemia, arrhythmia and glaucoma, can reduce the incidence and / or deathrate of cardiovascular diseases, improves the compliance of taking medicine by patients, and enhances the life quality of the patients.

Description

technical field [0001] The present invention relates to a novel pharmaceutical composition, which is composed of the following parts: a certain amount of calcium ion antagonist or its pharmaceutically acceptable salt, a certain amount of angiotensin converting enzyme inhibitor or its pharmaceutically acceptable salt. The invention relates to an acceptable salt, a certain amount of statins or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier; it also relates to a kit containing the above-mentioned active substances, belonging to the technical field of medicine. Background technique [0002] Due to the development of social economy and the change of people's lifestyle, the prevalence rate of hypertension in our country shows a continuous growth trend. According to the results of the national nutrition and health status survey in 2002, the prevalence rate of hypertension among adults in my country reached 18.8%. 160 million hypertensive patient...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K38/05A61K31/675A61K31/505A61K31/47A61K31/4709A61K31/4422A61P3/06A61P3/10A61P9/00A61P9/06A61P9/10A61P9/12A61P13/12A61P27/06A61K31/403A61K31/40A61K31/366
Inventor 王丽燕
Owner 王丽燕
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap